Quick Answer
Marker Therapeutics, Inc. reported Earnings Per Share Diluted of $0.79 (loss) per share for the year ending 2025.
- Marker Therapeutics, Inc. showed an increase of +33.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2015 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $0.09 (loss) per share | Q2 2015: $1.80 (loss) per share | Q3 2015: $4.23 per share | Q2 2016: $0.35 per share | Q3 2016: $0.29 (loss) per share | Q2 2017: $0.22 (loss) per share | Q3 2017: $0.39 (loss) per share | Q1 2021: $0.16 (loss) per share | Q2 2021: $0.13 (loss) per share | Q3 2021: $0.15 (loss) per share | Q1 2022: $1.19 (loss) per share | Q2 2022: $1.11 (loss) per share | Q3 2022: $0.83 (loss) per share | Q1 2023: $0.57 (loss) per share | Q2 2023: $0.29 per share | Q3 2023: $0.34 (loss) per share | Q1 2024: $0.27 (loss) per share | Q2 2024: $0.25 (loss) per share | Q3 2024: $0.26 (loss) per share | Q1 2025: $0.40 (loss) per share | Q2 2025: $0.29 (loss) per share | Q3 2025: $0.12 (loss) per share.
- Over the full 9 years of available data (2015 to 2025), Marker Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 91.5%.
- Historical annual values: Fiscal year 2025: $0.79 (loss) per share | Fiscal year 2024: $1.19 (loss) per share | Fiscal year 2023: $0.94 (loss) per share | Fiscal year 2022: $3.58 (loss) per share | Fiscal year 2021: $5.47 (loss) per share | Fiscal year 2020: $0.61 (loss) per share | Fiscal year 2017: $1.16 (loss) per share | Fiscal year 2016: $0.72 (loss) per share | Fiscal year 2015: $9.30 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: